Analysis of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores in typically developing individuals and those with Prader-Willi syndrome.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 Nov 2023
Historique:
received: 30 09 2023
accepted: 21 11 2023
medline: 27 11 2023
pubmed: 24 11 2023
entrez: 23 11 2023
Statut: epublish

Résumé

The Hyperphagia Questionnaire for Clinical Trials (HQ-CT) is an observer-reported outcome measure that has been widely used in interventional studies to assess changes in hyperphagic behaviors in individuals with Prader-Willi syndrome (PWS). However, HQ-CT scores in the wider PWS population and the general population have not been reported. Here we report HQ-CT scores from more than 400 individuals with PWS and 600 typical individuals, aged 5-26. Overall, HQ-CT scores were significantly higher in those with PWS compared to typically developing individuals at all ages evaluated. In addition, while HQ-CT scores in the typically developing population decreased with age, scores increased with age in PWS. To further understand the variability of HQ-CT scores in the PWS population, semi-structured interviews were conducted with caregivers of a small subset of adults with PWS who had unexpectedly low HQ-CT scores. These caregivers reported that strict adherence to a food routine, food security measures and supervised food preparation reduced the frequency and intensity of hyperphagic behaviors measured by HQ-CT. Thus, hyperphagic behaviors are captured by the HQ-CT for most individuals with PWS, but for some individuals residing in settings with highly structured food routines, HQ-CT scores may not fully reflect the extent of PWS-associated hyperphagia.

Identifiants

pubmed: 37996659
doi: 10.1038/s41598-023-48024-5
pii: 10.1038/s41598-023-48024-5
pmc: PMC10667498
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20573

Informations de copyright

© 2023. The Author(s).

Références

J Neurodev Disord. 2021 Jun 21;13(1):25
pubmed: 34148559
Diabetes Obes Metab. 2017 Dec;19(12):1751-1761
pubmed: 28556449
PLoS One. 2021 Mar 25;16(3):e0248739
pubmed: 33765021
J Clin Endocrinol Metab. 2023 Jun 16;108(7):1676-1685
pubmed: 36639249
J Med Econ. 2018 Dec;21(12):1230-1237
pubmed: 30256699
J Endocrinol Invest. 2015 Dec;38(12):1249-63
pubmed: 26062517
Curr Pediatr Rev. 2019;15(4):207-244
pubmed: 31333129
PLoS One. 2018 Mar 26;13(3):e0194655
pubmed: 29579119
Am J Med Genet A. 2011 May;155A(5):1040-9
pubmed: 21465655
J Clin Endocrinol Metab. 2023 Jun 16;108(7):1696-1708
pubmed: 36633570
Genet Med. 2012 Jan;14(1):10-26
pubmed: 22237428
Genes (Basel). 2019 Sep 14;10(9):
pubmed: 31540108
Obesity (Silver Spring). 2007 Jul;15(7):1816-26
pubmed: 17636101
J Appl Res Intellect Disabil. 2022 Mar;35(2):460-470
pubmed: 34904341

Auteurs

Lisa Matesevac (L)

Foundation for Prader-Willi Research, Covina, CA, USA.

Caroline J Vrana-Diaz (CJ)

Foundation for Prader-Willi Research, Covina, CA, USA.

Jessica E Bohonowych (JE)

Foundation for Prader-Willi Research, Covina, CA, USA.

Lauren Schwartz (L)

Foundation for Prader-Willi Research, Covina, CA, USA.
Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA.

Theresa V Strong (TV)

Foundation for Prader-Willi Research, Covina, CA, USA. theresa.strong@fpwr.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH